Please assess the completion status of the following clinical trial:

Trial Title: EndoPredict® Extended Endocrine Trial (EXET)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* At least 18 years of age at time of enrollment~* Able to provide informed consent~* ER+, HER2- breast tumor~* Stage T1-T3~* Currently receiving endocrine therapy~* Are between 4 and 6.5 years post-invasive breast cancer diagnosis~* Have all available information to produce an EPclin score, including treatment-naïve tumor stage, nodal status, and sufficient amount of remaining tissue from biopsy or resection to perform genomic testing (section 9)~* Patient and physician are willing to consider a change in endocrine therapy~Exclusion Criteria:~* Metastatic disease or currently active additional cancer diagnosis (except non- melanoma skin cancer) or any second primary breast cancer (includes ductal and/or lobular carcinoma in situ)~* Patient received systemic chemotherapy within 1 year of enrollment~* Currently enrolled in an interventional clinical trial or other clinical trial that precludes freely making decisions regarding extended endocrine therapy~* More than 3 positive nodes~* Received neo-adjuvant treatment (new-adjuvant chemotherapy or neo-adjuvant endocrine therapy)~* Are beyond 7 years post-breast cancer diagnosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with primary invasive ER+ HER2- breast cancer (Type: None): Distant recurrence-free survival (DRFS) between years 5 and 10 post-diagnosis of women with ER+, HER2- breast cancer who are classified as low risk according to their EPclin score and who did not receive extended endocrine therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).